New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 17, 2012
10:44 EDTJAZZFDA warns against use of Xyrem with alcohol, CNS depressant drugs
The FDA is reminding healthcare professionals and patients that the combined use of Xyrem (JAZZ) with alcohol or central nervous system depressant drugs can markedly impair consciousness and may lead to severe breathing problems. The use of alcohol with Xyrem is a new contraindication added to the Xyrem label, which already contraindicates its use with insomnia drugs. The use of Xyrem with other CNS depressant drugs such as opioid analgesics, benzodiazepines, sedating antidepressants or antipsychotics, general anesthetics, and muscle relaxants should generally be avoided. FDA recently evaluated reports of patients who died while taking Xyrem along with alcohol or other CNS depressants. The cause of these deaths is not clear because the reports contained incomplete information and did not adequately address confounding factor. Given some of the circumstances noted in the deaths, however, FDA determined that the recommendations in the Xyrem drug label should be strengthened to more strongly remind healthcare professionals and patients of the risks when using Xyrem with CNS depressant drugs or alcohol. Reference Link
News For JAZZ From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 24, 2014
08:15 EDTJAZZJazz Pharmaceuticals price target raised to $201 from $163 at Canaccord
Subscribe for More Information
October 17, 2014
07:53 EDTJAZZJazz Pharmaceuticals shares 'signifincantly undervalued,' says FBR Capital
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use